Search
for

    Learn

    5 / 801 results

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community ASATONA AG and "Asatex"

       4 upvotes 7 years ago
      The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

      community GT20029 - Promising phase II results

      in Research/Science  15 upvotes 2 years ago
      GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

      community 1 year Fin/2 months GHK-CU update

      in Update  128 upvotes 2 weeks ago
      The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

      community ghk-cu is potent 5-ar inhibitor?

      in Product  10 upvotes 2 years ago
      GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.